个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Liu Yun[1,2] * ; Li Yang[1,2] * ; Wang Yuxi[2,3] * ; Lin Congcong[2] ; Zhang Dan[2] ; Chen Juncheng[2] ; Ouyang Liang[1,2] ; Wu Fengbo[4] ; Zhang Jifa[1,2] ; Chen Lei[1] ;
机构： [1]Department of Neurology, Joint Research Institution of Altitude Health, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. [2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China. [3]Targeted Tracer Research and Development Laboratory, Frontiers Science Center for Disease‑Related Molecular Network, Institute of Respiratory Health, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. [4]Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
出处：
DOI： 10.1186/s13045-022-01310-7

关键词： VEGFR kinase Antitumor drugs Dual inhibitor Antiangiogenesis treatment

摘要：
Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis. Currently, VEGFR inhibitors have been widely used in the treatment of various tumors. However, current VEGFR inhibitors are limited to a certain extent due to limited clinical efficacy and potential toxicity, which hinder their clinical application. Thus, the development of new strategies to improve the clinical outcomes and minimize the toxic effects of VEGFR inhibitors is required. Given the synergistic effect of VEGFR and other therapies in tumor development and progression, VEGFR dual-target inhibitors are becoming an attractive approach due to their favorable pharmacodynamics, low toxicity, and anti-resistant effects. This perspective provides an overview of the development of VEGFR dual-target inhibitors from multiple aspects, including rational target combinations, drug discovery strategies, structure-activity relationships and future directions.© 2022. The Author(s).

基金：
This review was supported by the National Natural Science Foundation of China (81903502, 81922064, 81874290); Sichuan Science and Technology Program (2019YFS0003); and National Major Scientific and Technological Special Project for Significant New Drugs Development (2018ZX09201018-021).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 血液学 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 血液学 1 区 肿瘤学
第一作者：
第一作者机构： [1]Department of Neurology, Joint Research Institution of Altitude Health, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. [2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Neurology, Joint Research Institution of Altitude Health, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. [2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China.
推荐引用方式(GB/T 7714)：
Liu Yun,Li Yang,Wang Yuxi,et al.Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy[J].Journal of hematology & oncology.2022,15(1):89.doi:10.1186/s13045-022-01310-7.
APA：
Liu Yun,Li Yang,Wang Yuxi,Lin Congcong,Zhang Dan...&Chen Lei.(2022).Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.Journal of hematology & oncology,15,(1)
MLA：
Liu Yun,et al."Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy".Journal of hematology & oncology 15..1(2022):89

相关文献

[1]抗肿瘤药物创新皮下制剂临床应用的药事服务专家共识 [2]Design, synthesis, and biological evaluation of novel dual inhibitors of heat shock protein 90/mammalian target of rapamycin (Hsp90/mTOR) against bladder cancer cells [3]Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice. [4]Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma. [5]Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. [6]Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors. [7]国家医保谈判抗肿瘤药品支付限定条件的循证医学证据变迁 [8]Dual-target inhibitors based on COX-2: a review from medicinal chemistry perspectives [9]Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality. [10]A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment.

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号